Across TCGA pan-cancer cohorts, FAM66A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM66A data layer compared with 21 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher FAM66A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM66A expression acts as an unfavorable survival marker.

SARC are the cancer types where FAM66A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.098	0.611	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: FAM66A tumor-vs-normal RNA expression · all FAM66A data types